Capital Markets & Financing
A China fund from Fidelity is beating the crowd. How it plans to keep doing it
Fidelity’s China Focus Fund is setting up for another year of outperformance, after ranking first last year among China equity funds tracked by Morningstar.
SoftBank-backed Neumora Therapeutics files for U.S. IPO
Neumora Therapeutics, a biopharmaceutical firm backed by biotech Amgen and Japan's SoftBank, on Friday filed for an initial public offering of its shares in New York.
China says the best way to ‘de-risk’ is to restore stability with the U.S.
China’s Ministry of Commerce said Thursday that restoring stability in U.S.-China trade relations is the best way to 'de-risk' — a twist to a term that’s become popular in international politics.
Sinovac Confirms Receipt of an Unsolicited Partial Tender Offer
Sinovac confirmed today that it is aware of an unsolicited partial tender offer from Alternative Liquidity Index LP to purchase up to a maximum of 10,000,000 shares of the Company, representing approximately 10.05% of the Company’s outstanding shares, for $0.03 per share in cash.
Epigenic Therapeutics Announces $32 Million in Series A Funding to Bring Breakthrough Epigenome Medicine to Clinical Development
Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, today announced that it has raised $32 million in Series A round of financing.
妙顺生物完成超亿元A轮融资，凯乘资本担任独家财务顾问
近日，妙顺（上海）生物科技有限公司（以下简称：妙顺生物）宣布完成超亿元A轮融资，本轮融资由中科海创领投，毅达资本、高瓴创投(GL Ventures)、泰坦科技（688133.SH）、同毓基金跟投，凯乘资本担任独家财务顾问。本轮融资获得了国家队基金、著名投资机构以及上市公司的认可和支持，募集资金将主要用于加速一系列原代细胞及配套试剂耗材产品的开发，以及进一步加强企业海内外商业化拓展能力。
The China contagion that never was
Markets aren’t worried about China contagion – and you shouldn’t be, either.
Will NEUCA be taken over by the Chinese?
According to unofficial information from the authors, talks are underway about the acquisition of a controlling stake in Neuci by a consortium of Chinese companies, including Sinopharma.
The CSRC launched a series of policies tightening IPOs
2023年8月27日，在万众期待之下，证监会推出了一系列救市政策，包括降低印花税、IPO收紧、降低两融保证金、规范减持等多项内容。
The China Securities Regulatory Commission coordinates the balance of the primary and secondary markets and optimizes the regulatory arrangements for IPOs and refinancing
The China Securities Regulatory Commission (CSRC) announced on 27 August that the CSRC fully considers the current market situation, improves the counter-cyclical adjustment mechanism of the primary and secondary markets, and makes arrangements around reasonably grasping the rhythm of IPO and refinancing.
